---
title: "Obefazimod (ABX464) in Ulcerative colitis: Tumor necrosis factor inhibitors"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Tumor necrosis factor inhibitors. Topics: Recommendations for anti-TNF therapy: ACG 2025 guideline; Pivotal trial efficacy of infliximab, adalimumab, and golimumab: ACG 2025 guideline; Efficacy tiers by prior advanced-therapy exposure: AGA 2024 living guideline; Lymphoma risk with TNF antagonists: AGA 2024 living guideline; 3 further topics. 7 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/tumor-necrosis-factor-inhibitors"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Tumor necrosis factor inhibitors

<a id="heading-2.2.2.1.4"></a>

## 2.2.2.1.4 Tumor Necrosis Factor Inhibitors

<a id="topic-2.2.2.1.4-1"></a>

### Recommendations for anti-TNF therapy: ACG 2025 guideline

> “28. In patients with moderately to severely active UC, we recommend anti-tumor necrosis factor (TNF) therapy using infliximab for induction of remission (Strong recommendation, high quality of evidence).”
> “29. In patients with moderately to severely active UC, we recommend anti-TNF therapy using adalimumab or golimumab for induction of remission (Strong recommendation, moderate quality of evidence).”
> “42. We recommend continuing anti-TNF therapy using adalimumab, golimumab, or infliximab (IV or SC dosing) for maintenance of remission after anti-TNF induction in patients with prior moderately to severely active UC (Strong recommendation, moderate quality of evidence).”
> “45. Infliximab is the preferred anti-TNF therapy for patients with moderately to severely active UC.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.4-2"></a>

### Pivotal trial efficacy of infliximab, adalimumab, and golimumab: ACG 2025 guideline

> “In ACT 1, 39% and 32% of patients receiving infliximab at 5 mg/kg and 10 mg/kg, respectively, attained remission at week 8 (primary endpoint), compared with 15% of patients receiving placebo (P < 0.003 for both doses of infliximab). In ACT 2 at week 8, 34% and 28% of patients receiving infliximab at 5 and 10 mg/kg, achieved remission, respectively, compared with 6% of patients receiving placebo (P < 0.001 for both comparisons).”
> “The overall rates of clinical remission at week 8 were 16.5% for those receiving adalimumab and 9.3% among those receiving placebo (P = 0.019); at week 52, those receiving adalimumab were in remission 17.3% of the time compared with those receiving placebo at 8.5% (P = 0.004).”
> “The phase 3 results identified rates of clinical response at week 6 in patients receiving 200/100 mg and 400/200 mg golimumab of 51.0% and 54.9%, respectively, compared with 30.3% among those receiving placebo (both, P ≤ 0.0001) (180).”
> “All 3 anti-TNF agents have demonstrated superiority over placebo in achieving the primary endpoints of response and remission, but there have been no head-to-head trials comparing the agents with one another (182–184).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.4-3"></a>

### Efficacy tiers by prior advanced-therapy exposure: AGA 2024 living guideline

> “In patients who are naïve to advanced therapies, the AGA suggests using a higher efficacy medication (infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab) or an intermediate efficacy medication (golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab), rather than a lower efficacy medication (adalimumab).”
> “In patients who have previously been exposed to one or more advanced therapies, particularly tumor necrosis factor-α (TNF) antagonists, the AGA suggests using a higher efficacy medication (tofacitinib, upadacitinib, ustekinumab) or an intermediate efficacy medication (filgotinib, mirikizumab, risankizumab, guselkumab), rather than a lower efficacy medication (adalimumab, vedolizumab, ozanimod, etrasimod).”
> “Infliximab has a possibly important benefit in achieving remission compared with adalimumab, mirikizumab, tofacitinib, and filgotinib with a low certainty of evidence.”
> “Notably, there was no RCT for infliximab or golimumab in patients with prior exposure to biologics.”

Source: [Singh et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12162142/)

<a id="topic-2.2.2.1.4-4"></a>

### Lymphoma risk with TNF antagonists: AGA 2024 living guideline

> “In a French population-based study, Lemaitre and colleagues estimated the annual incidence of lymphoma in patients treated with TNF antagonist monotherapy vs. unexposed patients to be 0.41 per 1000 person-years vs. 0.26 per 1000 person-years; after adjusting for potential confounders, the risk of lymphoma was 2.4-times higher in patients treated with TNF antagonist monotherapy25.”
> “Patients exposed to combination therapy had six-fold increased risk of lymphoma, as compared to unexposed patients, and 2.3–2.5 times higher risk as compared to patients exposed to monotherapy with either agent.”

Source: [Singh et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12162142/)

<a id="topic-2.2.2.1.4-5"></a>

### Recommendations and meta-analysis for anti-TNF agents: ECCO 2026 guideline

> “We recommend treatment with anti-tumor necrosis factor agents [infliximab, adalimumab, and golimumab] for the induction of remission in moderate-to-severe ulcerative colitis [strong recommendation, moderate certainty of evidence] [Agreement: 98%]”
> “We recommend anti-tumor necrosis factor agents [infliximab, adalimumab, and golimumab] for the maintenance of remission in patients with ulcerative colitis who responded to induction therapy with the same drug [strong recommendation, high certainty of evidence] [Agreement: 100%]”
> “Our meta-analysis revealed evidence of efficacy for induction of clinical remission [RR: 2.23; 95% CI: 1.81–2.76] and clinical response [RR: 1.56; 95% CI: 1.38–1.76].”
> “Anti-TNF agents were effective for the maintenance of clinical remission [RR: 1.98; 95% CI: 1.60–2.45], steroid-free clinical remission [RR: 2.86; 95% CI: 1.67–4.90], sustained clinical remission [RR: 2.76; 95% CI: 1.78–4.28], and improvement in QoL [RR: 1.71; 95% CI: 1.27–2.32].”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

<a id="topic-2.2.2.1.4-6"></a>

### Boxed warning for TNF blockers: infliximab label

> “WARNING: SERIOUS INFECTIONS and MALIGNANCY”
> “Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis) and infections due to other opportunistic pathogens.”
> “Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including REMICADE.”
> “Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF blockers including REMICADE.”
> “The majority of REMICADE cases were reported in patients with Crohn’s disease or ulcerative colitis, most of whom were adolescent or young adult males.”

Source: [Remicade prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/103772s5412lbl.pdf)

<a id="topic-2.2.2.1.4-7"></a>

### Adalimumab limitation of use after TNF blocker failure

> “The effectiveness of HUMIRA has not been established in patients who have lost response to or were intolerant to TNF blockers”
> “Forty percent (40%) of subjects enrolled in Study UC-II had previously used another TNF-blocker.”

Source: [Humira prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125057s425lbl.pdf)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
